Examination of antimicrobial activity of selected non-antibiotic medicinal preparations

Acta Poloniae Pharmaceutica - Drug Research

Volumn 69, Issue 6, 2012, Pages 1368-1371

  Kruszewska, Hanna ^a   Zarȩba, Tomasz ^a   Tyski, Stefan ^a,b  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Antimicrobial activity; Candida albicans; Drugs; Escherichia coli; Non antibiotics; Pseudomonas aeruginosa; Staphylococcus aureus

Indexed keywords

ARKETIS; ATOMOXETINE; ATROPINE; BENCYCLANE; BENCYCLANE FUMARATE; BETAHISTINE; BISOPROLOL FUMARATE; BISOPROMERCK; BUFLOMEDIL; BUPIVACAINE; CATALIN; CEFOTETAN; CINNARIZINE; DONEPEZIL; FEBANTEL; FENOFIBRATE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; HYDROXYZINE; INHALOL; IOMEPROL; KALDYUM; LAFACTIN; LOZAP; NATURAL PRODUCT; NICLOSAMIDE; NIMESULIDE; NORIFAZ; OSELTAMIVIR; PAROXETINE; RISEDRONIC ACID; RISPERIDONE; TIANEPTINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPRO RATIOPHARM CHRONO; VALPROIC ACID; VALSARTAN; VENLAFAXINE;

ANTIMICROBIAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG CONTROL; DRUG MANUFACTURE; DRUG SCREENING; ESCHERICHIA COLI; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLAND; STAPHYLOCOCCUS AUREUS;

ANTI-INFECTIVE AGENTS; MICROBIAL SENSITIVITY TESTS;

EID: 84870929231     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kristiansen J.E.: ASM NEWS 57, 135 (1991).
2. Williams J.D.: J. Antimicrob. Chemother. 35, 721 (1995).
3. Tyski S.: Acta Pol. Pharm. Drug Res. 66, 401 (2003).
4. Guttmann P., Ehrlich, P.: Berl. Klin. Wochenschr. 39, 953 (1891).
5. Hendricks O., Butterworth TS., Kristiansen JE.: Int. J. Antimicrob. Agents 22, 242 (2003).
6. Molnar J., Ren, J., Kristiansen, J. E.: Antonie van Leeuwenhoek 62, 315 (1992).
7. Kruszewska H., Zarȩba T., Tyski S.: Acta Pol. Pharm. Drug Res. 57 Suppl., 117, (2000).
8. Kruszewska H., Zarȩba T., Tyski S.: Acta Pol. Pharm. Drug Res. 59, 436, (2002).
9. Kruszewska H., Zarȩba T., Tyski S.: Acta Pol. Pharm. Drug Res. 61 Suppl., 436, (2004).
10. Kruszewska H., Zarȩba T., Tyski S.: Acta Pol. Pharm. Drug Res. 63, 457, (2006).
11. Kruszewska H., Zarȩba T., Tyski S.: Pharmaceutical Scientific Review (Farmaceutyczny Przegla̧d Naukowy) (in Polish) No. 2 (37), 19 (2008).
12. Kruszewska H., Zarȩba T., Tyski S.: Acta Pol. Pharm. Drug Res. 65, 779 (2008).
13. Kruszewska H., Zarȩba T., Tyski S.: Acta Pol. Pharm. Drug Res. 67, 733 (2010).
14. Amaral L., Kristiansen, J. E., Lorian, V.: J. Antimicrob. Chemother. 30, 556 (1992).
15. Martins M., Dastidar S.G., Fanning S., Kristiansen J.E., Molnar J., Pages J., Schelz Z., Viveiros M., Amaral L.: Int. J. Antimicrob. Agents 31, 198 (2008).
16. Comes J., Beelman R., J. Food Prot. 65, 476 (2002)
17. Chen M., Jensen B., Zhai L., Colding H., Kristiansen JE.: Int. J. Antimicrob. Agents 19, 195 (2002).
18. European Pharmacopoeia - 7, 2011.
19. Clonts L.: Microbial Limit and Bioburden Tests: Validation approaches and global requirements, Interpharm Press, Inc., Buffalo Grove (1998).
20. Podlewski J.K., Chwalibogowska-Podlewska A.: Leki Współ czesnej Terapii (Drugs for Contemporary Therapy) (in Polish) 20st edn., Medical Tribune, Warszawa 2010.